What the Agence Octo White-Label Readiness Screen looks for
Agence Octo's White-Label Readiness Screen is an internal sourcing methodology that looks for four entity-level signals in FDA 510(k) records: non-US filing geography, repeat clearances under the same holder, product-family concentration in the snapshot, and overlap with Agence Octo's sourcing-category lens.
Agence Octo's June 2026 filter first narrowed the FDA CDRH snapshot to tracked consumer-health categories, then ranked entities by cleared 510(k) count inside that filter. Here, "tracked consumer-health categories" means Agence Octo's buyer-facing device lenses used in this article, including Respiratory & Sleep, Rehab & Neurotech, and Wearable Biosensors. The 86-company filter refers to unique clearance-holder entities with at least one cleared 510(k) in those tracked categories in Agence Octo's 2026-06-04 FDA snapshot. Classification was then applied at the entity level, not the product level, using four visible signals: filing geography, repeat clearances under the same holder, product-family concentration in the snapshot, and overlap with Agence Octo's sourcing-category lens. "Standout" means the entity matched all four signals in this screen; "watchlist" means it matched some but not all; "weaker white-label signal" means filing volume was visible but the holder structure looked less useful for direct white-label scouting. This is Agence Octo methodology, not an FDA designation.
| Screen factor | What it may suggest | What it does not prove | Source bucket |
|---|---|---|---|
| Non-US manufacturer entity appears as clearance holder | The company may control more of the product and export process directly | It does not prove OEM availability or private-label willingness | Bucket 1 — FDA CDRH public database |
| Repeat filings under the same entity | The company may have an active quality and submission system | It does not prove current production capacity | Bucket 1 — FDA CDRH public database |
| Product family consistency | By Agence Octo methodology, the company may be building around one technical lane instead of one-off filings | It does not prove line depth or margin fit | Bucket 1 + Bucket 4 — FDA data + Agence Octo lensing methodology |
| Device lens overlaps with buyer sourcing category | By Agence Octo methodology, the company may be commercially relevant to the buyer's search | It does not prove the cleared product can be adapted for another brand | Bucket 4 — Agence Octo Periscope methodology |
Watch the stack, not any single signal.
A 510(k) record on its own is not proof of white-label readiness. But a non-US holder with repeat filings in one product family is the cleanest shortlist signal in this June snapshot. This is Agence Octo methodology.
The shortlist from this month
In this month's visible top 10, Unimed Medical Supplies and Kunshan Hi-Fortune Health Products classify as Standout by Agence Octo methodology, while Epic Medical, Fisher & Paykel Healthcare, and Breas Medical classify as Watchlist.
From the 10 highest-volume clearance holders in Agence Octo's June 2026 filter, two companies classify as Standout and three more land on the Watchlist as white-label scouting signals.
| Rank | Company | Geography | Clearances in June 2026 filter | Agence Octo category lens | Visible product-family signal in snapshot | Agence Octo classification |
|---|---|---|---|---|---|---|
| 1 | Unimed Medical Supplies, Inc. | Shenzhen, China | 9 | Wearable Biosensors | Reusable finger clip SpO2 sensors | Standout |
| 2 | Epic Medical Pte. Ltd. | Singapore | 9 | Rehab & Neurotech | Bag access and closed-system products | Watchlist |
| 3 | Cepheid | US | 8 | Respiratory & Sleep | Molecular diagnostic filings in tracked filter | Weaker white-label signal |
| 4 | Roche Molecular Systems | US | 7 | Respiratory & Sleep | Molecular diagnostic filings in tracked filter | Weaker white-label signal |
| 5 | Abbott Molecular | US | 6 | Respiratory & Sleep | Molecular diagnostic filings in tracked filter | Weaker white-label signal |
| 6 | Kunshan Hi-Fortune Health Products Co., Ltd. | Kunshan, China | 5 | Rehab & Neurotech | Electrically powered wheelchairs | Standout |
| 7 | Sleepnet | US | 5 | Respiratory & Sleep | Sleep and respiratory mask-related filings in tracked filter | Weaker white-label signal |
| 8 | Medline | US | 5 | Respiratory & Sleep | Mixed finished-device filings in tracked filter | Weaker white-label signal |
| 9 | Fisher & Paykel Healthcare | New Zealand | 5 | Respiratory & Sleep | Respiratory support product-family concentration | Watchlist |
| 10 | Breas Medical | Sweden | 5 | Respiratory & Sleep | Ventilation and respiratory support concentration | Watchlist |
The table above reconciles the visible evidence used in this article: 10 companies, 65 cleared 510(k) submissions combined in Agence Octo's June 2026 filter. The companies discussed below are the strongest white-label scouting signals in this visible top-10 set by Agence Octo methodology, not necessarily the highest-quality suppliers in market.
1) Unimed Medical Supplies, Inc. — Shenzhen, China — 9 clearances
Unimed is the clearest operator signal in this list.
Per the FDA CDRH public database, the entity is based in Shenzhen and holds 9 cleared 510(k) submissions in Agence Octo's Wearable Biosensors lens. Sample products in the snapshot include reusable finger clip SpO2 sensors. That pattern matters because it shows repeat filings around a narrow device family rather than scattered submissions across unrelated categories. (Bucket 1 — FDA CDRH public database; Bucket 4 — Agence Octo Periscope lensing)
This does not prove Unimed offers private-label terms. It sets the burden of proof in the right direction. A China-based holder with repeated filings in reusable sensor hardware is a stronger sourcing lead than a distributor with one imported listing and no filing history. This is Agence Octo methodology.
2) Kunshan Hi-Fortune Health Products Co., Ltd. — Kunshan, China — 5 clearances
Hi-Fortune is a different type of signal.
Per the FDA CDRH public database, the company holds 5 cleared 510(k) submissions tied to electrically powered wheelchairs. The product family concentration is unusually tight in this snapshot. That usually points to a company working inside one manufacturing lane rather than testing adjacent categories. (Bucket 1 — FDA CDRH public database; Bucket 4 — Agence Octo Periscope methodology)
For buyers scouting mobility or rehab hardware, that is useful. It suggests process repetition, product-family depth, and export familiarity. It does not confirm channel strategy, engineering flexibility, or willingness to support a Western house brand. This is a sourcing signal, not regulatory confirmation.
3) Epic Medical Pte. Ltd. — Singapore — 9 clearances
Epic Medical sits in a more ambiguous position, but it still belongs on the watchlist.
Per the FDA CDRH public database snapshot, Epic Medical holds 9 cleared 510(k) submissions in Agence Octo's Rehab & Neurotech lens. The filing count is tied for highest in this filter. The sample products listed in the digest include bag access and closed-system products, which suggests repeat activity in a defined product lane. That product description is operational rather than consumer-facing: the signal here is repeated filings in a narrow access-system category, not a claim about end-market branding. (Bucket 1 — FDA CDRH public database; Bucket 4 — Agence Octo Periscope methodology)
Singapore-based holders can be worth watching because they may sit closer to manufacturing control than some US brand entities do. That does not prove Epic is an OEM-first counterparty. It means the entity structure deserves follow-up instead of dismissal. This is Agence Octo methodology.
Why some high-filing companies are weaker white-label signals
High filing volume alone does not make a company white-label-ready. In this screen, several US-based holders rank high on 510(k) count but classify as weaker white-label signals because the holder structure may be less useful for direct factory-first outreach.
The top-10 table includes US-based names such as Cepheid, Roche Molecular Systems, Abbott Molecular, Sleepnet, and Medline.
A US clearance holder with multiple filings may be a strong commercialization, channel, or category-momentum indicator. It is usually a weaker starting point for white-label scouting because the filing entity is more likely to be the brand owner, marketer, or finished-device company rather than the factory you can contract with directly. This is Agence Octo methodology.
That is a pattern, not a rule. Corporate structures vary. Some brand entities own manufacturing. Some foreign entities are pure paper holders. The record tells you where to look next. It does not finish the diligence.
June 2026 pattern to notice
Among the top 10 holders in this filter:
- 5 companies are US-based
- 2 companies are China-based
- 1 is Singapore-based
- 1 is New Zealand-based
- 1 is Sweden-based
Respiratory & Sleep appears most often in the visible top 10, while Rehab & Neurotech and Wearable Biosensors also appear. (Bucket 1 — FDA CDRH public database; Bucket 4 — Agence Octo category mapping)
For sourcing teams, that split matters.
If you are looking for white-label or OEM-capable leads, the most useful names are not always the most famous names. They are the entities where filing geography, repeat submission behavior, and product-family concentration line up.
That is the shortlist logic behind this month's screen.
What to do with this list
Use this list as a first-pass sourcing screen, then verify the commercial and manufacturing facts the FDA record does not show.
Start with the holders that pass the stack:
- non-US filing entity,
- repeat clearances,
- narrow product-family concentration,
- category overlap with your sourcing lane.
Then verify the parts the FDA record cannot tell you: factory ownership, engineering scope, MOQ logic, post-market support, and whether the filing entity is the manufacturer you would actually contract with. One explicit warning: the clearance holder entity and the physical factory are not always the same thing, so do not assume a non-US holder automatically equals direct factory access. This is Agence Octo methodology.
If you are building a broader shortlist, pair this screen with Agence Octo's supplier-shortlisting approach before outreach.